Pediatric Rheumatology

You have full text access to this OnlineOpen article

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

  1. H. M. Albers1,
  2. J. A. M. Wessels1,
  3. R. J. H. M. van der Straaten1,
  4. D. M. C. Brinkman1,
  5. L. W. A. Suijlekom-Smit2,
  6. S. S. M. Kamphuis2,
  7. H. J. Girschick3,
  8. C. Wouters4,
  9. M. W. Schilham1,
  10. S. le Cessie1,
  11. T. W. J. Huizinga1,
  12. R. ten Cate1,*,
  13. H. J. Guchelaar1,†

Article first published online: 30 DEC 2008

DOI: 10.1002/art.24087

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 1, pages 46–51, 15 January 2009

Additional Information

How to Cite

Albers, H. M., Wessels, J. A. M., van der Straaten, R. J. H. M., Brinkman, D. M. C., Suijlekom-Smit, L. W. A., Kamphuis, S. S. M., Girschick, H. J., Wouters, C., Schilham, M. W., le Cessie, S., Huizinga, T. W. J., ten Cate, R. and Guchelaar, H. J. (2009), Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis & Rheumatism, 61: 46–51. doi: 10.1002/art.24087

Author Information

  1. 1

    Leiden University Medical Center, Leiden, The Netherlands

  2. 2

    Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands

  3. 3

    University of Wurzburg, Wurzburg, Germany

  4. 4

    Gasthuisberg University Hospital, Leuven, Belgium

  1. †

    Dr. Guchelaar holds a patent for methotrexate pharmacogenetics.

*Department of Pediatrics, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands

Publication History

  1. Issue published online: 30 DEC 2008
  2. Article first published online: 30 DEC 2008
  3. Manuscript Accepted: 11 SEP 2008
  4. Manuscript Received: 13 MAY 2008

Funded by

  • Dutch Arthritis Association. Grant Numbers: NR-05-1-403, KFS-04-2-202

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

REFERENCES

  • 1
    Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002; 29: 1520–30.
  • 2
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390–2.
  • 3
    Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, et al. Current medication choices in juvenile rheumatoid arthritis II: update of a survey performed in 1993. J Clin Rheumatol 2001; 7: 295–300.
  • 4
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al, for the Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043–9.
  • 5
    Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849–57.
    Direct Link:
  • 6
    Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 316–20.
  • 7
    Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al, for the Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191–201.
    Direct Link:
  • 8
    Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67: 370–4.
  • 9
    Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 249–55.
  • 10
    Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163–72.
  • 11
    Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 1832–6.
  • 12
    Wessels JA, Kooloos WM, De Jonge R, Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006; 54: 2830–9.
    Direct Link:
  • 13
    Wessels JA, Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54: 1087–95.
    Direct Link:
  • 14
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9.
  • 15
    Ruperto N, Ravelli A, Falcini F, Lepore L, Buoncompagni A, Gerloni V, et al, and the Italian Pediatric Rheumatology Study Group. Responsiveness of outcome measures in juvenile chronic arthritis. Rheumatology (Oxford) 1999; 38: 176–80.
  • 16
    Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al, and the Italian Pediatric Rheumatology Study Group. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 38–41.
  • 17
    Brik R, Gepstein V, Berkovitz D. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids. Clin Rheumatol 2005; 24: 612–4.
  • 18
    Cush JJ. Early rheumatoid arthritis: is there a window of opportunity? J Rheumatol Suppl 2007; 80: 1–7.
  • 19
    Quinn MA, Cox S. The evidence for early intervention. Rheum Dis Clin North Am 2005; 31: 575–89.
View Full Article (HTML) Get PDF (75K)